piperacillin--tazobactam-drug-combination and Cholangitis

piperacillin--tazobactam-drug-combination has been researched along with Cholangitis* in 8 studies

Reviews

1 review(s) available for piperacillin--tazobactam-drug-combination and Cholangitis

ArticleYear
Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa treated with colistin; a case report and review of the literature.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:12

    A 77-year-old man had undergone left-lobe liver resection and a choledochojejunostomy six years previously, and thereafter he suffered from a postoperative relapse of cholangitis. He was admitted to our hospital due to liver abscesses and bacteremia caused by multidrug-resistant Pseudomonas aeruginosa. Empirical treatment with piperacillin/tazobactam was started, and the patient initially recovered. However, he developed a second case of sepsis caused by piperacillin/tazobactam-resistant P. aeruginosa bacteremia originating from a new liver abscess. We changed the piperacillin/tazobactam to colistin and flomoxef and continued the two antibiotics for one month. During the antibiotic therapy, the patient successfully underwent bile duct stent placement.

    Topics: Aged; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cholangitis; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Kidney; Liver Abscess, Pyogenic; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections

2013

Trials

1 trial(s) available for piperacillin--tazobactam-drug-combination and Cholangitis

ArticleYear
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    International journal of antimicrobial agents, 2005, Volume: 25, Issue:1

    In the present study 24 hospitalized patients requiring empirical antibiotic treatment were randomly assigned to receive the beta-lactam antibiotic/beta-lactamase inhibitor combination piperacillin-tazobactam either as an intermittent or as a continuous infusion. According to pharmacokinetic modelling, the daily dose was reduced by 33% in patients receiving continuous infusion compared with intermittent infusion. Dose reduction because of impaired renal function was required in the intermittent dosing group for 5 of 12 patients compared with 1 of 12 patients in the continuous infusion group. However, the mean daily dose in the continuous group was 15% less than the intermittent infusion group. Mean serum concentrations of piperacillin were to 39.0 microg/ml after the end of bolus distribution, exceeding by far the minimal inhibitory concentration of the most clinically relevant pathogens. The corresponding mean value for tazobactam was 6.3 microg/ml. Pharmacokinetic/pharmacodynamic modelling suggests that both treatment schemes should produce virtually identical anti-infective responses to sensitive, intermediate and resistant strains. In the present study the continuous infusion of piperacillin/tazobactam provided adequate antibacterial activity over the 24-h dosing period and offers the potential for a substantial reduction in the total daily dose.

    Topics: Adult; Aged; Anti-Bacterial Agents; Cholangitis; Community-Acquired Infections; Cross Infection; Drug Administration Schedule; Female; Fever of Unknown Origin; Hospitalization; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Prospective Studies; Treatment Outcome; Urinary Tract Infections

2005

Other Studies

6 other study(ies) available for piperacillin--tazobactam-drug-combination and Cholangitis

ArticleYear
Changing Patterns of Causative Pathogens over Time and Efficacy of Empirical Antibiotic Therapies in Acute Cholangitis with Bacteremia.
    Gut and liver, 2022, 11-15, Volume: 16, Issue:6

    To select appropriate empirical antibiotics, updates on the changes in pathogens are essential. We aimed to investigate the changes in pathogens and their antibiotic susceptibility in acute cholangitis (AC) with bacteremia over a period of 15 years. Furthermore, the efficacy of empirical antibiotic therapies and the risk factors predicting antibiotic-resistant pathogens (ARPs) were analyzed.. A total of 568 patients with AC and bacteremia who were admitted to Daegu Catholic University Medical Center from January 2006 to December 2020 were included. Their medical records were retrospectively reviewed. In addition, the data were grouped and analyzed at 3-year intervals under the criteria of Tokyo Guideline 2018.. During the study period, 596 pathogens were isolated from blood cultures of 568 patients. The three most common pathogens were. The proportion of VRE has increased and CRE has emerged in AC. In addition, healthcare-associated infection, history of previous biliary intervention, and the severity of AC were independent risk factors predicting ARP. For patients with these risk factors, the administration of imipenem or piperacillin-tazobactam should be considered.

    Topics: Anti-Bacterial Agents; Bacteremia; Cholangitis; Humans; Imipenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Retrospective Studies

2022
Infectious complications of non-surgical biliary tract manipulation in paediatric patients. Role of antibiotic prophylaxis.
    Enfermedades infecciosas y microbiologia clinica (English ed.), 2022, Volume: 40, Issue:10

    Infections related to non-surgical manipulation of the biliary tract (NSMBT) are common events despite periprocedural antibiotic prophylaxis (PAP). Since June 2017, our local protocol has indicated a 24-h regimen of intravenous piperacillin-tazobactam for this purpose.. We aimed to describe the incidence and characteristics of NSMBT-related paediatric infections, define risk factors for their development, and analyse adherence to our PAP protocol.. Epidemiological, clinical, and microbiological data were collected in consecutive NSMBT procedures performed in paediatric patients (<18 years) in our centre (2010-2019).. 113 procedures in 37 patients, median age 4 years (IQR 1-8), were included. Main underlying diseases were biliary atresia (32%) and cancer (14%). Sixty-eight percent had undergone liver transplant and 70% hepaticojejunostomy. In 44 procedures (39%), the intervention was performed during the course of infection and previously prescribed antibiotic treatment was maintained. In the other 69, PAP was specifically indicated for NSMBT; antibiotic adequacy increased from 35% to 100% after June 2017. In total, 32 NSMBT-related infections (28%) occurred, mainly in the first 24h post-procedure (72%); no deaths happened. Causative pathogens were Gram-negative rods (64%), Gram-positive cocci (28%), and Candida spp. (8%). Main related risk factors were hepaticojejunostomy, biliary obstruction, and liver transplant.. NSMBT in children entails a significant infection risk, even under antibiotic prophylaxis, being hepaticojejunostomy the main risk factor. Infectious complications mainly occurred immediately after the procedure. After establishing a PAP protocol, 100% of interventions received appropriate prophylaxis, decreasing antibiotic exposure time and potentially, the length of hospital stay.

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Biliary Tract; Child; Child, Preschool; Cholangitis; Humans; Infant; Piperacillin, Tazobactam Drug Combination

2022
Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021, Volume: 40, Issue:8

    With rising antibiotic resistance, alternatives to carbapenems are needed for acute cholangitis (AC). Temocillin reaches high biliary concentrations with limited impact on microbiota. We retrospectively included 140 AC episodes and assessed the efficacy of temocillin using microbiology susceptibility testing from blood cultures. Considering all bacteria collected by episode, resistance to temocillin, PIP/TAZ and 3GC occurred in 27/140 (26%), 32 (22.8%) and 31 (22%) episodes, respectively (pā€‰=ā€‰0.7). After documentation, temocillin could have spared PIP/TAZ or carbapenems in 14/26 and 4/11 episodes. Temocillin may constitute an alternative treatment after microbiological documentation by sparing carbapenems and/or PIP/TAZ, but not as an empirical therapeutic option.

    Topics: Anti-Bacterial Agents; Bacterial Infections; Cholangitis; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Penicillins; Piperacillin, Tazobactam Drug Combination; Retrospective Studies

2021
Bacteremia with Raoultella planticola in the setting of acute pancreatitis complicated with acute cholangitis.
    Revista espanola de enfermedades digestivas, 2017, Volume: 109, Issue:6

    The bacterium Raoultella planticola (R planticola) is a rare pathogen in humans. We report a case of mild acute pancreatitis (MAP) of biliary origin with cholangitis and bacteremia with R planticola in association with pancreatic panniculitis (PP). We present the case report of a 55-year-old woman.

    Topics: Acute Disease; Anti-Bacterial Agents; Bacteremia; Cholangitis; Enterobacteriaceae; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Pancreatitis, Acute Necrotizing; Panniculitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination

2017
Cholangitis with septic shock caused by Raoultella planticola.
    Journal of medical microbiology, 2012, Volume: 61, Issue:Pt 3

    Raoultella planticola (formerly Klebsiella planticola) is a Gram-negative bacterium that has been rarely reported in association with human infection. Here we describe a case of cholangitis complicated with septic shock caused by R. planticola in an immunocompromised patient with advanced cancer who underwent endoscopic retrograde cholangiopancreatography to extract common bile duct stones. The infection was cleared by piperacillin-tazobactam treatment.

    Topics: Aged; Anti-Bacterial Agents; Cholangitis; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Immunocompromised Host; Male; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Shock, Septic; Treatment Outcome

2012
Raoultella planticola bacteraemia.
    Journal of medical microbiology, 2012, Volume: 61, Issue:Pt 10

    Topics: Anti-Bacterial Agents; Bacteremia; Cholangitis; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination

2012